MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors.
Lun-Xi PengGuang-Ling JieAn-Na LiSi-Yang LiuHao SunMei-Mei ZhengJia-Ying ZhouJia-Tao ZhangXu-Chao ZhangQing ZhouWen-Zhao ZhongJin-Ji YangHai-Yan TuJian SuHong-Hong YanYi-Long WuPublished in: Experimental hematology & oncology (2021)
MET amplification identified by FISH remains the optimal biomarker to identify suitable candidates for MET-TKI therapy. In comparison, amplification identified by NGS seems not as robust to be effective predictive biomarker. Further exploration is needed regarding the focal amplification by NGS in predicting the efficacy.